21.09.2023 II International scientific and practical conference "Sustainable forestry"
1. Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей. Методические рекомендации. ‒ Версия 2 (03.07.2020). 2. Кантемирова М.Г. Детский мультисистемный воспалительный синдром, ассоциированный с новой коронавирусной инфекцией (COVID-19): актуальная информация и клиническое наблюдение // Педиатрическая фармакология. – 2020. 3. Детский мультисистемный воспалительный синдром, ассоциированный с новой коронавирусной инфекцией (COVID-19) / под ред. Овсянникова Д. Ю., Петряйкиной Е. Е. – 2020 4. World Health Organization. Listings of WHO’s response to COVID-19. https://www.who.int/ru/news/item/29-06- 2020-covidtimeline. 5. COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University. https://coronavirus.jhu.edu/map.html 6. Vehar S, Boushra M, et al. Post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’. Cleveland Clinic Journal of Medicine. 2021; 88 (5):267-272. DOI: https://doi.org/10.3949/ccjm.88a.21010 7. National Institute for Health and Care Excellence: Clinical Guidelines. In COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19; National Institute for Health and Care Excellence: London, UK. 2020; www. nice.org.uk/guidance/ng188 8. ICD-10 – International Statistical Classification of Diseases and Related Health Problems 10 revision. https://mkb-10. com/index.php?pid=23014 9. Hu B, Guo H, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19 (3): 141-154. DOI:10.1038/s41579-020-00459-7 10. Wang MY, Zhao R, et al. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol. 2020; 10: 587269. DOI: 10.3389/fcimb.2020.587269 11. Zou X Chen, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020; 14: 185–192. DOI: 10.1016/j. bbrc.2020.03.044 12. Zhang H, Penninger JM, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46: 586–590. DOI: 10.1007/s00134- 020-05985-9 13. Hoffmann M, Kleine-Weber H, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181 (2): 271–280. DOI: 10.1016/j.cell.2020.02.052 Fogarty H, Townsend L, et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J Thromb Haemost. 2021; 19 (10): 2546-2553. DOI: 10.1111/jth.15490. 14. von Meijenfeldt FA, Havervall S, Adelmeijer J, et al. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. Blood A d v. 2 0 2 1 ; 5 ( 3 ) : 7 5 6 - 7 5 9 . D O I : 1 0 . 11 8 2 / bloodadvances.2020003968 15. Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020; 7 (8): e575-e582. DOI: 10.1016/S2352-3026(20)30216-7 16. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020; e3319. DOI:10.1002/dmrr.3319 17. Yang JK, Lin SS, et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010; 47 (3): 193–199. DOI: 10.1007/s00592-009-0109-4. 18. Wei L, Sun S, Xu CH, et al. Pathology of the thyroid in severe acute respiratory syndrome. Hum Pathol. 2007; 38 (1): 95-102. DOI: 10.1016/j.humpath.2006.06.011 19. Brancatella A, Ricci D, et al. Subacute Thyroiditis After Sars-COV-2 Infection. J Clin Endocrinol Metab. 2020; 105 (7): dgaa276. DOI:10.1210/clinem/dgaa276 20. Leow MK, Kwek DS, et al. Hypocortisolism in survivors of severe acute respiratory syndrome (SARS). Clin Endocrinol (Oxf). 2005; 63 (2): 197-202. DOI: 10.1111/j.1365-2265.2005.02325.x 21. Ling Ma, Wen Xie, et al. Effect of SARS-CoV-2 infection upon male gonadal function: A single centerbased study. MedRxiv . 2020; https://www.medrxiv. org/content/10.1101/2020.03.21.20037267v2 DOI: 10.1101/2020.03.21.20037267 22. Starace M, Iorizzo M, Sechi A, et al. Trichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management. JAAD Int. 2021; 5: 11-18. DOI: 10.1016/j. jdin.2021.07.006 23. Sharquie KE, Jabbar RI. COVID-19 infection is a major cause of acute telogen effluvium [published online ahead of print, 2021 Aug 31]. Ir J Med Sci. 2021; 1-5. DOI: 10.1007/ s11845-021-02754-5 24. Aksoy H, Yıldırım UM, et al. COVID-19 Induced Telogen Effluvium [published online ahead of print, 2021 Oct 27]. Dermatol Ther. 2021; e15175. DOI: 10.1111/ dth.15175
SCIENCE & INNOVATION